HCPCS G0465 is officially defined as "Autologous platelet rich plasma (prp) or other blood-derived product for diabetic chronic wounds/ulcers, using an fda-cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)." HCPCS G0465 is referenced in 9 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Sentara Health Plans, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0465 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Multiple medical policies are changing effective February 1, 2026, with significant coverage expansions for cardiovascular biomarker testing (CPT 85384, 85385) and bronchial valves, plus numerous additions of covered ICD-10 codes across various services. Several prior authorization requirements are shifting to online authorization tools while some digital health therapies are moving from not medically necessary to contract exclusions.
Sentara Health Plans relaxed prior authorization requirements for 499 codes for commercial products offered in Virginia, covering categories such as medical and surgical supplies, cardiovascular procedures, proprietary laboratory analyses and outpatient PPS codes. Effective February 1, 2026, commercial prior authorization is required for a further set of codes, several psychological testing codes now require authorization only after the listed hour limits, and several commercial codes, including 99070, A9286, G0330 and S9152, are not covered. Self-funded commercial products had separate prior authorization and not-covered code lists effective February 1, 2026, and Medicaid changes took effect October 1, 2025 and December 1, 2025.
CareSource will enforce a provider type requirement for Ohio Medicaid home health claims: only Provider Type 60 (Medicare Certified Home Health Agencies) may bill G-codes for home health services. Claims submitted with G-codes from any other provider type will be denied. Providers with incorrect provider type classifications must coordinate with the Ohio Department of Medicaid to update their records.
Premera Washington policy changes carry effective dates from April 1, 2026 through July 2, 2026, and all of those dates had passed as of 2026-11-05. Many listed codes now require review for medical necessity and prior authorization, and several services now require review for site of service, including Upper Gastrointestinal Endoscopy, Carpal Tunnel Release Surgical Treatments, and Shoulder Arthroscopy in Adults. Other changes mark specific procedures as investigational or not medically necessary, add or remove criteria for drugs, and add quantity limits for some medications.
Premera Washington policy changes carry effective dates from May 1, 2026 through September 4, 2026, and all of those dates had passed as of 2026-11-05. Several services now require review for medical necessity and prior authorization, including Prostate Artery Embolization, Hematopoietic Cell Transplantation for Acute Myeloid Leukemia, and Diagnosis and Treatment of Sacroiliac Joint Pain, and several drugs and procedures now also require review for site of service. Other changes add or remove drugs from pharmacy criteria, add quantity limits, extend initial authorization periods, and mark some procedures as investigational.
Premera Washington policy changes carry effective dates from June 1, 2026 through September 19, 2026, and all of those dates had passed as of 2026-11-05. Several codes now require review for medical necessity and prior authorization, including Prostate Artery Embolization (37243) and Radiation Oncology codes 77436 through 77439, which Carelon reviews effective June 5, 2026. Upper Gastrointestinal Endoscopy, Carpal Tunnel Release Surgical Techniques, and several listed drugs, including immune checkpoint inhibitors and immune globulin, now also require review for site of service, and shoulder arthrotomy criteria added conservative management requirements.
Policy 2.01.24, Platelet Rich Plasma and Growth Factor Treatments, states that platelet-rich plasma (PRP) and autologous platelet-derived preparations, including basic fibroblast growth factor, epidermal growth factor, and placental angiogenic growth factors, are investigational for all indications. The 01/22/26 annual update changed the policy title and deleted the policy statements for becalpermin gel. The policy also states that the AAOS guidelines for osteoarthritis of the hip and glenohumeral joint, and for rotator cuff injuries, do not recommend PRP for these conditions.
Aetna considers autologous chondrocyte implants medically necessary for repairing full thickness, focal chondral defects of the knee in members with disabling knee pain who meet all of the listed criteria, including age 15 or older with documented growth plate closure or age under 55, and BMI less than or equal to 35. The criteria also require failure of conservative therapy with a minimum of 6 weeks of physical therapy in the past year, and a focal grade IV defect on a load bearing surface of the femoral condyle or patella, sized 2 to 4 sq cm for arthroscopic cases and 2 to 8 sq cm for open cases. Aetna considers FDA-approved MACI an equally acceptable alternative to Carticel for these indications. Aetna considers autologous chondrocyte implants for ankle (talar) or other non-knee joint lesions experimental, investigational, or unproven, as well as autologous matrix-induced chondrogenesis (AMIC) for the lesions listed in the policy.
Clinical Policy Bulletin 0784 considers the following experimental, investigational, or unproven because their effectiveness has not been established: autologous blood injection and platelet-poor or platelet-rich plasma injection for all indications, plus specific listed uses of autologous platelet gel, adipose-tissue-derived stem cell injections, autologous fat injection and other blood-derived products. Listed uses include platelet-rich plasma for rotator cuff injuries, osteoarthritis and plantar fasciitis, autologous platelet gel after total knee arthroplasty and for diabetic foot ulcer, and autologous fat injection for carpometacarpal arthritis of the thumb and velopharyngeal insufficiency. The policy also lists CPT, HCPCS and ICD-10 codes as not covered for the indications it lists.
Watch G0465
Get one email when a payer policy names G0465, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for G0465
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for G0465 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.